S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Forecast & News

$2.15
+0.01 (+0.47 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$2.15
Now: $2.15
$2.26
50-Day Range
$1.63
MA: $2.73
$3.23
52-Week Range
$1.49
Now: $2.15
$7.25
Volume20,930 shs
Average Volume34,896 shs
Market Capitalization$28.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Read More
Merrimack Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.30 per share

Profitability

Net Income$-17,330,000.00

Miscellaneous

Employees27
Market Cap$28.77 million
Next Earnings Date4/1/2020 (Estimated)
OptionableOptionable

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.


Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

How has Merrimack Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MACK stock has decreased by 22.1% and is now trading at $2.15. View which stocks have been mosted impacted by Coronavirus.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, April 1st 2020. View our earnings forecast for Merrimack Pharmaceuticals.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.14. View Merrimack Pharmaceuticals' earnings history.

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals declared a -- dividend on Wednesday, December 4th. Stockholders of record on Monday, December 16th will be given a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date of this dividend is Friday, December 13th. View Merrimack Pharmaceuticals' dividend history.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Shares of Merrimack Pharmaceuticals reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Media stories about MACK stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merrimack Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMerrimack Pharmaceuticals.

Who are some of Merrimack Pharmaceuticals' key competitors?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Rite Aid (RAD), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Novavax (NVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Exelixis (EXEL), Bausch Health Companies (BHC) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the following people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 56)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $2.15.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $28.77 million. Merrimack Pharmaceuticals employs 27 workers across the globe. View additional information about Merrimack Pharmaceuticals.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com/.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  400 (Thanks for Voting!)
Underperform Votes:  297 (Thanks for Voting!)
Total Votes:  697
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel